Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LittleGuy2on Jul 02, 2021 12:28pm
160 Views
Post# 33483298

RE:AGM results

RE:AGM resultsAgreed DaveW...fingers crossed for some positive change:


"With more than 20% of the shares voted, this is the largest shareholder participation in the Company's recent history. Approximately 1.3% of shareholders opposed the motions. The results of the vote for the election of directors are as follows: James Howard-Tripp - 56% votes for / Rory Riggs - 76% votes for / Harry Glorikian - 70% votes for / Garth MacRae - 70% votes for"

Suggests some shareholders with large blocks of shares opposed the current BOD &/or their direction.  A 56% suggests no confidence in the CEO.  Not sure how the current CEO adds value to this company.  Hopefully, the new board members will bring something to the table to support growth.

<< Previous
Bullboard Posts
Next >>